Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

TSRI Stroke Drug Demonstrates Safety in Clinical Trial

By Scripps Research Institute | February 28, 2018

A preliminary Phase 2 clinical trial has demonstrated that patients with acute ischemic stroke, the most common type of stroke, can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug invented at The Scripps Research Institute (TSRI). The trial results, announced by pharmaceutical company ZZ Biotech, also show that 3K3A-APC substantially reduced hemorrhage volume and hemorrhage incidence in patients.

“These results lay the groundwork for the next steps toward FDA approval,” says John Griffin, PhD, professor at TSRI, whose team invented 3K3A-APC.

Stroke is the fifth leading cause of death in the United States and the number one cause of adult disability. Acute ischemic strokes occur when a clot blocks blood flow to the brain. To date, the FDA has approved only one drug treatment, called tissue plasminogen activator (tPA), to treat acute ischemic strokes. tPA helps break up blood clots if given within a 4.5-hour window after the stroke. 

Unfortunately, tPA’s use is limited due to this brief treatment window and its potential to cause bleeding in the brain and neuronal cell death. But studies so far show that 3K3A-APC could complement tPA administration. Griffin designed the experimental drug by modifying just three amino acids on a naturally occurring blood protein called protein C, which is both an anticoagulant and a cell protective agent.

“This is an extremely novel drug,” says Griffin.

Preclinical testing in collaborative studies involving Griffin’s lab and the lab of Berislav Zlokovic, MD, PhD, director of the Zilkha Neurogenetic Institute at the University of Southern California, showed that 3K3A-APC lessens the damage of stroke and protects brain cells from the side effects of tPA. The drug was licensed by TSRI to the pharmaceutical company ZZ Biotech, where Zlokovic was the scientific founder. 

To find the maximally tolerated dose, the National Institutes of Health’s National Institute of Neurological Disorders and Stroke (NINDS) funded the recent Phase 2 study, called RHAPSODY, through a grant to the principal investigator Patrick Lyden, MD, chair of the Department of Neurology at Cedars-Sinai in Los Angeles, and through a NeuroNEXT Infrastructure Resource Access grant to ZZ Biotech, where Kent Pryor, PhD, served as co-principal investigator. NINDS entered into a Cooperative Research and Development Agreement (CRADA) with ZZ Biotech.

For the placebo-controlled dose-escalation trial, the researchers evaluated 3K3A-APC in patients with acute ischemic stroke treated with intravenous tPA, intra-arterial thrombectomy, or both. The scientists evaluated four doses of the drug: 120, 240, 360 and 540 µg/kg. Study participants, aged 18 to 90, were followed for 90 days. All doses were deemed safe and well tolerated.

As a secondary endpoint, the researchers evaluated cerebral hemorrhage in these patients. They found that total hemorrhage volume and hemorrhage incidence were both substantially reduced in 3K3A-APC-treated patients. The incidence of any hemorrhage was reduced from 86.5 percent in placebo-treated patients to 67.4 percent in the combined treatment arms. Total hemorrhage volume was likewise reduced from an average of 2.1±5.8 mL on placebo to 0.8±2.1 mL in the combined treatment arms.

The next steps for the researchers are to confirm and extend the successful Phase 2 study results in larger clinical trials.

Griffin says the collaborative environment at TSRI made the development of 3K3A-APC possible. “I’ve been blessed by working with fantastic people. TSRI has been committed to basic research and discovery of new knowledge, especially with translational potential—and that’s been my philosophy.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE